News

April 23, 2019

Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy

February 20, 2019

Fulcrum Therapeutics Appoints Christopher Moxham, Ph.D. as SVP, Discovery

January 4, 2019

Fulcrum Therapeutics to Present at Biotech Showcase 2019

January 3, 2019

Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer

September 5, 2018

Fulcrum Therapeutics Announces $80 Million Series B Financing

August 14, 2018

Fulcrum Therapeutics Promotes Diego Cadavid, M.D., to Senior Vice President, Clinical Development

June 27, 2018

Fulcrum Therapeutics Strengthens Board of Directors with Appointment of Kate Haviland

May 21, 2018

Fulcrum Therapeutics and the FSHD Clinical Trial Research Network Announce Clinical Trial Readiness Study

March 15, 2018

Fulcrum Therapeutics to Present at BioCentury’s Future Leaders in the Biotech Industry Conference

November 10, 2017

Fulcrum Therapeutics to Present at the Annual Society for Neuroscience Meeting

October 11, 2017

Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

September 25, 2017

Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference

September 5, 2017

Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

August 9, 2017

Fulcrum Therapeutics Named Finalist for the 2017 Xconomy Awards in the Patient Partnership Category

December 7, 2016

Fulcrum Therapeutics Appoints Renowned Experts in CNS Disorders and Muscular Dystrophies to Serve on Newly Formed Scientific Advisory Board

September 19, 2016

FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

July 19, 2016

Third Rock Ventures Launches Fulcrum Therapeutics with $55 Million Series A Investment